Tenderwize
Wróć do wyszukiwania

Omalizumab Discount Agreement Open House

Techniker Krankenkasse·Hamburg, Germany·Deadline Jun 30, 2028 · 675 days left·Open·Supplies
Zarejestruj się, aby zapisaćOpen documents
Structured notice only
Oryginalny tytuł ogłoszenia

Germany – Pharmaceutical products – Open House Biologika Rabattverträge 2026 - 18 Omalizumab

60/100

Ocena szansy

Needs reviewLow complexity
SuppliesOpen
Skąd ta ocena?

Szansa

60 / 100

Złożoność

20 / 100

Czynniki ryzyka

No indication of estimated contract value or expected volume; revenue depends on actual prescriptions and number of par...

The notice explicitly states this is not a public procurement under EU directives; legal remedies lie with social court...

Głęboka analiza portfolio

Głęboka analiza dopasowania firmy

Wykorzystuje:

  • Description
  • Industries & Services
  • Capabilities
  • Market & Experience
  • Certifications

Przegląd

Moderate opportunity

Kluczowe fakty

  • Supplies contract
  • 1 lot
  • Duration until Jun 2028
  • Conclusion of discount agreements (Rabattverträge) for the active substance Omalizumab
  • Standardized contract terms no individualized negotiations
Pokaż pełne podsumowanie

Open house procedure by Techniker Krankenkasse (TK) for discount agreements (Rabattverträge) on the active substance Omalizumab. The procedure allows any qualified pharmaceutical entrepreneur to join at any time during the contract term (max 24 months until 30.06.2028). No exclusivity, no individual negotiations, and no estimated value provided. Eligibility requires being a pharmaceutical entrepreneur with a valid marketing authorization for the product. Award criteria are not specified. Submission is via email (with qualified electronic signature) or postal mail. Important: This is not a public procurement in the traditional sense; legal remedies lie with social courts, not procurement chambers.

Ryzyka

No indication of estimated contract value or expected volume; revenue depends on actual prescriptions and number of par...

The notice explicitly states this is not a public procurement under EU directives; legal remedies lie with social court...

Analiza może być niepełna

Przeanalizowano tylko część dokumentacji. Pozostałe dokumenty mogą zawierać dodatkowe wymagania, certyfikaty lub dokumenty do złożenia.

Kluczowe wymagania

Technical

  • Must be a pharmaceutical entrepreneur under § 4 Abs. 18 AMG with a valid marketing authorization for Omalizumab

Eligibility

  • Must submit a self-declaration (Anlage 4) confirming eligibility and reliability

Administrative

  • Contract can be signed at any time during the term but for timely inclusion in pharmacy software documents must be received by the 3rd of the previous month

Wymagania mogą być niepełne.

Kryteria udzielenia

Lot 1

No award criteria specified; the procedure is open to all qualified participants with standardized conditions.

Zamawiający

Lokalizacja

Hamburg, DEU

Identyfikator

992-80116-93

Działalność

Health

Części (1)

LOT-0001

Omalizumab Discount Agreement Open House

Single lot covering all discount agreements for Omalizumab. The TK aims to conclude rebate contracts with all eligible pharmaceutical entrepreneurs under § 130a Abs. 8 SGB V.

SuppliesEU fundedElectronic submission

Lokalizacja

DE600, Germany

Czas trwania

Jun 2026 - Jun 2028

Kategoria

Pharmaceutical products

Kryteria udzielenia

No award criteria specified; the procedure is open to all qualified participants with standardized conditions.

Termin

Deadline Jun 30, 2028

Szczegóły zamówienia

Data publikacji
20 May 2026
Języki
German

Metadane referencyjne

Podstawa prawna
32014L0024

Identyfikatory referencyjne

ID przetargu
349347-2026

Dokumenty (1)

Dokument zamówienia 1

Podobne przetargi

Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells über Arzneimittel mit dem Handelsnamen Orylmyte(R) (ATC-Code nach WHO: V01AA03)

Aug 31

Bulgaria – Pharmaceutical products – Динамична система за покупки за доставка на лекарствени продукти за Медицински институт на МВР

Jul 9

Belgium – Pharmaceutical products – Antimycotica

Aug 27

Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells über Arzneimittel mit dem Handelsnamen Oralair(R) (ATC-Code nach WHO: V01AA02)

Aug 31

Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells zum Wirkstoff Ipratropiumbromid (ATC-Code nach WHO: R03BB01)

Sep 30

Denmark – Pharmaceutical products – Amgros 2027 1.1170.a

Sep 3